Anemia Clinical Trial
Official title:
An Observational Study Designed to Elucidate the Pathways by Which Low-grade Inflammation Contributes to Anaemia in Rural African Children From 6 Months to 2 Years of Age
Investigator have previously shown that hepcidin is up-regulated even by low levels of
inflammation and, according to our prior stable isotope studies, is predicted to block iron
absorption. In this follow-up observational study, investigator aim to elucidate the
potential drivers of this low-grade inflammation and to recalibrate the relationship between
hepcidin and iron absorption using a more direct measure of absorption than the stable
isotope method which measures the net of absorption and utilization. Investigator will study
120 ostensibly well children (6-24m) living in the rural region of West Kiang.
Investigator will:
1. Use detailed clinical screening for possible origins of the low grade inflammation.
2. Assess iron absorption and its relationship to iron and anaemia status, inflammation,
EPO, erythroferrone and hepcidin.
Aim 1:
Hypothesis 1: 'Minor' but persistent infections of the respiratory tract, skin, mouth, and
gut cause chronic elevation of hepcidin levels and other markers of infection including CRP.
Research Question 1: What is the relationship between each of the following: CRP, hepcidin,
clinical score of skin infections; clinical score of oral health; clinical score of
respiratory infections; and systemic markers of gut damage and bacterial translocation (serum
EndoCAB and iFABP) and stool markers of inflammation (calprotectin, REG1b and lipocalin2).
Hypothesis 2: Respiratory infections and airway inflammation are the most common cause of low
grade inflammation.
Research Question 2: What is the most common source(s) of persistent low-grade inflammation
in apparently well children living in rural Gambia.
Aim 2:
Hypothesis: Hepcidin levels above 5.5ng/ml block oral iron absorption.
Research Question: What is the relationship between hepcidin and oral iron absorption in well
children living in rural Gambia?
Aim 3:
Hypothesis: Anaemic children with low-grade inflammation have anaemia of inflammation with
concomitant iron deficiency that results in inappropriately low levels of EPO production and
reticulocytosis for their erythroid mass (Hb levels) levels.
Research Question: Is there decreased EPO synthesis and/or increased EPO resistance in
anaemic children with low-grade inflammation living in rural Gambia?
Aim 4:
Hypothesis: First investigator will conduct a hypothesis-free exploratory analysis to assess
whether erythroferrone behaves as predicted based upon mouse models (ie up-regulated by
stress erythropoiesis and inversely related to hepcidin). Investigator additionally
hypothesize that there may be a vicious cycle initiated by inflammation and then perpetuated
by the consequent low levels of (iron-restricted) erythropoiesis, leading to low
erythroferrone and loss of hepcidin suppression.
Research Question: What is the relationship between erythroferrone, iron status,
inflammation, hepcidin, EPO in anaemic and non-anaemic children with and without low-grade
inflammation living in rural Gambia? Primary: To examine in detail the pathways by which
low-grade inflammation causes iron deficiency anaemia in African children.
Secondary: To assess if anaemia of inflammation and resistance to erythropoietin play a role
in causing and perpetuating anaemia in children living in rural Africa.
This is an observational study of 120 children who will be recruited at the routine
vaccination clinics or pre-scheduled well-child check-ups at the Keneba clinic. Each child
will be seen three times (at 6, 12 and 18 months) and the same protocol will be used at each
visit.
Figure 1: Study design At each visit, children will be examined by the Research Clinician or
PI using pre-determined validated checklists for possible sources of low-grade inflammation.
Each participant will be given a clinical score for skin conditions, oral health, and
respiratory infections/airway disease.
After the clinical examination, an oral iron absorption protocol will be initiated:
Step 1: A venous blood sample will be collected and assayed for full blood count (including
reticulocyte count) and serum iron markers, hepcidin, erythropoietin (EPO), erythroferrone,
IL-6 and EndoCab; Step 2: Children will be given an oral dose of liquid ferrous fumarate at
2mg/kg; Step 3: Between 3-4 hours later a venous blood sample will be drawn for measurement
serum iron markers. The change in serum iron levels (measured before and after dosing) will
be used as a direct measurement of iron absorption.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Completed |
NCT03341338 -
Genes-in-Action - Hepcidin Regulation of Iron Supplementation
|
||
Completed |
NCT00060398 -
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT05384691 -
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
|
Phase 2 | |
Not yet recruiting |
NCT06309641 -
Methemoglobinemia Following Intravenous Iron Treatment
|
||
Completed |
NCT02912533 -
A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02930850 -
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
|
N/A | |
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Completed |
NCT02912494 -
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT03822884 -
Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT02384122 -
Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
|
Phase 3 | |
Completed |
NCT02603250 -
Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda
|
N/A | |
Completed |
NCT02176759 -
Iron Absorption From Rice Fortified With Ferric Pyrophosphate
|
N/A | |
Completed |
NCT01922479 -
Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure
|
Phase 4 | |
Withdrawn |
NCT01934842 -
A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate
|
N/A | |
Completed |
NCT02310113 -
Transfusion and Skeletal Muscle Tissue Oxygenation
|
N/A | |
Completed |
NCT01693029 -
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
|
Phase 3 | |
Completed |
NCT01458028 -
Age and Gender Effects on the Pharmacokinetics of BAY85-3934
|
Phase 1 | |
Completed |
NCT01432717 -
Study of ACE-536 in Healthy Postmenopausal Women
|
Phase 1 |